In 2025, Neuropace's return on assets (ROA) was -0.31, a -25.81% increase from the -0.41 ROA in the previous year.

Neuropace Aktienanalyse

What does Neuropace do?

Neuropace Inc is a US-based company specializing in the development and manufacturing of medical devices. It is headquartered in Mountain View, California and has been operating since 2000. The company was founded as a spin-off from a study conducted by Dr. Martha Morrell at Stanford University, focusing on the treatment of epilepsy with implanted devices. Neuropace Inc's business model involves manufacturing and marketing medical devices for epilepsy treatment. These devices, known as neurostimulators, are implantable devices that send electrical impulses to the brain and can reduce epileptic seizures. The company has been involved in various areas of epilepsy treatment, including the development of devices for patients with pharmacoresistant focal epilepsies. These devices can be implanted in patients who do not respond to traditional treatments such as medications or surgeries. Neuropace Inc has also started focusing on the development of devices for epilepsy diagnosis. One of these devices is the ambulatory EEG monitor, which records brain activity and allows doctors to better detect epilepsy seizures. The company has launched a range of products to achieve its goal of enabling patients to have a better quality of life. The key product is the RNS neurostimulator, which is implanted in patients and continuously monitors brain activity using electrodes placed in the brain to monitor brain waves. When the neurostimulator detects unusual activity, it automatically sends impulses to the brain to prevent or reduce the occurrence of epileptic seizures. The benefit is that patients experience fewer seizures and can better organize and plan their daily lives. Neuropace Inc has a competitive position in the market with its products for treating pharmacoresistant focal epilepsies. The RNS neurostimulator is the only device approved by the US Food and Drug Administration FDA capable of reducing critical neurological outcomes in epilepsy. The company also has a strong presence in the field of epilepsy diagnosis, particularly with the ambulatory EEG monitor. Neuropace Inc has also formed strategic partnerships with other companies to bring its technologies to the market. The company has formed alliances with Medtronic, among others, for the marketing and distribution of the RNS neurostimulator. Through these partnerships, Neuropace Inc has expanded its reach in the market and strengthened its relationships with leading companies in the industry. In summary, Neuropace Inc is a company specializing in the development and manufacturing of medical devices for epilepsy treatment. The company has expanded its technologies to cover a broader range of epilepsy conditions and has achieved a high level of success with its products. With solid partnerships and a strong commitment to epilepsy treatment, Neuropace Inc is expected to continue leading the market for medical devices. Neuropace ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Neuropace's Return on Assets (ROA)

Neuropace's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Neuropace's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Neuropace's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Neuropace’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Neuropace stock

What is the Return on Assets (ROA) of Neuropace this year?

The Return on Assets (ROA) of Neuropace is -0.31 undefined this year.

What was the ROA of Neuropace compared to the previous year?

The ROA of Neuropace has increased by -25.81% compared to the previous year.

What consequences do high ROA have for investors of Neuropace?

A high ROA is advantageous for investors of Neuropace, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Neuropace?

A low ROA can be unfavorable for investors of Neuropace as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Neuropace affect the company?

An increase in ROA of Neuropace can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Neuropace impact the company?

A reduction in the ROA of Neuropace can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Neuropace?

Some factors that can influence the ROA of Neuropace include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Neuropace important for investors?

The ROA of Neuropace is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Neuropace take to improve ROA?

To improve ROA, Neuropace can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Neuropace pay?

Over the past 12 months, Neuropace paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Neuropace is expected to pay a dividend of 0 USD.

What is the dividend yield of Neuropace?

The current dividend yield of Neuropace is .

When does Neuropace pay dividends?

Neuropace pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Neuropace?

Neuropace paid dividends every year for the past 0 years.

What is the dividend of Neuropace?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Neuropace located?

Neuropace is assigned to the 'Health' sector.

Wann musste ich die Aktien von Neuropace kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Neuropace from 2/18/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/18/2025.

When did Neuropace pay the last dividend?

The last dividend was paid out on 2/18/2025.

What was the dividend of Neuropace in the year 2024?

In the year 2024, Neuropace distributed 0 USD as dividends.

In which currency does Neuropace pay out the dividend?

The dividends of Neuropace are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Neuropace

Our stock analysis for Neuropace Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Neuropace Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.